MedTrace Logo

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

NCT04208347 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 580

Last updated 2026-01-23

No results posted yet for this study

Summary

The study is being conducted to evaluate the efficacy, safety and tolerability of chemotherapy and apatinib with or without camrelizumab in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Conditions

  • Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

Interventions

DRUG

Apatinib 250mg

Apatinib 250mg

DRUG

Camrelizumab

Camrelizumab 200mg

DRUG

S-1, Oxaliplatin

S-1, Oxaliplatin, q3w

DRUG

Apatinib 500mg

Apatinib 500mg

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Zhenggang Zhu · Ruijin Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-18
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04208347 on ClinicalTrials.gov